Exact Mass: 319.1027262
Exact Mass Matches: 319.1027262
Found 111 metabolites which its exact mass value is equals to given mass value 319.1027262,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Tetrodotoxin
A quinazoline alkaloid that is a marine toxin isolated from fish such as puffer fish. It has been shown to exhibit potential neutotoxicity due to its ability to block voltage-gated sodium channels. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker Tetrodotoxin. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=4368-28-9 (retrieved 2024-09-06) (CAS RN: 4368-28-9). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
Ibandronate
Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures. M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
Salbutamol 4-O-sulfate
C13H21NO6S (319.10895260000007)
Salbutamol 4-O-sulfate is a metabolite of salbutamol. Salbutamol or albuterol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease. It is marketed as Ventolin among other brand names. Salbutamol was the first selective β2-receptor agonist to be marketed — in 1968. It was first sold by Allen & Hanburys under the brand name Ventolin. The drug was an instant success, and has been used for the treatment of asthma ever since. (Wikipedia)
5,9:7,10a-Dimethano-10aH-[1,3]dioxocino[6,5-d]pyrimidine-4,7,10,11,12-pentol, octahydro-12-(hydroxymethyl)-2-imino-,(4R,4aR,5R,7S,9S,10S,10aR,11S,12S)-
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins D049990 - Membrane Transport Modulators
1-(2-Methylbenzo[d]oxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea
N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline
C13H21NO6S (319.10895260000007)
(S)-2-(3,4-dihydroxybenzoylamino)-3-(3,4-dihydroxyphenyl)propanol|nigerrimin B
(1R*,3S*)-1-(5-hydroxymethylfuran-2-yl)-3-carboxy-6-hydroxy-8-methoxy-1,2,3,4-tetrahydroisoquinoline
2-(3,4-dihydro-2-methoxy-4-oxoquinazolinyl)-1H-indole-3-carboxaldehyde|orirenierine B
C18H13N3O3 (319.09568680000007)
Albuterol (Salbutamol-4-O-sulfate)
C13H21NO6S (319.10895260000007)
Ibandronate
M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
METHYL 2-((TERT-BUTOXYCARBONYL)AMINO)-5-(TRIFLUOROMETHYL)BENZOATE
METHYL 4-(ETHYLCARBAMOYL)-2,3-DIFLUORO-[1,1-BIPHENYL]-3-CARBOXYLATE
C17H15F2NO3 (319.1019944000001)
1-Azulenesulfonic acid, 3,8-dimethyl-5-(1-methylethyl)-, sodium salt, hydrate (2:2:1)
2-[2-(4-morpholin-4-ylanilino)-1,3-thiazol-4-yl]acetic acid
C15H17N3O3S (319.09905720000006)
N-(2,3-Dihydro-2-oxo-1H-benzimidazol-5-yl)-3-hydroxy-2-naphthalenecarboxamide
C18H13N3O3 (319.09568680000007)
4-(6-METHOXY-2-NAPHTHYL)-6-(TRIFLUOROMETHYL)PYRIMIDIN-2-AMINE
Ro 19-4603
C15H17N3O3S (319.09905720000006)
Methanone, [4-(4-chlorophenyl)-1-piperazinyl](3,5-dimethyl-4-isoxazolyl)
(E)-P,P-diphenyl-N-(1-phenylethylidene)phosphinic amide
Methanone, [4-(2-chlorophenyl)-1-piperazinyl](3,5-dimethyl-4-isoxazolyl)-
METHYL 2-((ISOPROPOXYCARBONYL)AMINO)-5-METHYL-4-(TRIFLUOROMETHYL)BENZOATE
[(1R)-1-(benzyloxycarbonylamino)-2-phenyl-ethyl]phosphinic acid
C16H18NO4P (319.09733980000004)
Ethyl 4-(2-(1,3-dioxoisoindolin-2-yl)ethoxy)-3-oxobutanoate
3-[3-Acetyl-4-hydroxy-2-(4-methoxy-phenyl)-5-oxo-2,5-dihydro-pyrrol-1-yl]-propionic acid
Methyl 3-(benzyloxy)-1-(2,2-dihydroxyethyl)-4-oxo-1,4-dihydropyridine-2-carboxylate
(3-Fluoro-4-(((4-methoxybenzyl)oxy)carbamoyl)phenyl)boronic acid
(11R,13S)-3-amino-5,12,13,14-tetrahydroxy-14-(hydroxymethyl)-8,10-dioxa-2-aza-4-azoniatetracyclo[7.3.1.17,11.01,6]tetradec-3-en-9-olate
ibandronic acid
M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline
C13H21NO6S (319.10895260000007)
(11S,13S)-3-Amino-5,12,13,14-tetrahydroxy-14-(hydroxymethyl)-8,10-dioxa-2-aza-4-azoniatetracyclo[7.3.1.17,11.01,6]tetradec-3-en-9-olate
1-[[(1,5-Dimethyl-3-pyrazolyl)-oxomethyl]amino]-3-(2-methoxyphenyl)thiourea
1-(4-Ethyl-2-pyridinyl)-3-(4-methylphenyl)sulfonylurea
C15H17N3O3S (319.09905720000006)
4-acetyl-3,5-dimethyl-1H-pyrrole-2-carboxylic acid (5-methoxycarbonyl-2-furanyl)methyl ester
N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro[3,2-d]pyrimidinamine
C18H13N3O3 (319.09568680000007)
(11S,13S)-3-amino-14-(hydroxymethyl)-8,10-dioxa-2,4-diazatetracyclo[7.3.1.17,11.01,6]tetradec-3-ene-5,9,12,13,14-pentol
(2S)-N-(4-chloro-2-methylphenyl)-2-(4-methoxyphenoxy)propanamide
Ro 67-7476
C17H18FNO2S (319.10422200000005)
Ro 67-7476 is a potent positive allosteric modulator of mGluR1 and potentiates glutamate-induced calcium release in HEK293 cells expressing rat mGluR1a with an EC50 of 60.1 nM[1][2]. Ro 67-7476 is a potent P-ERK1/2 agonist?and activates ERK1/2 phosphorylation in the absence of exogenously added glutamate (EC50=163.3 nM)[3].
18,19-dihydroxy-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4,6,8,15,17,19-octaen-14-one
C18H13N3O3 (319.09568680000007)
(1r,5r,6r,7r,9s,11s,12s,13s,14r)-14-(hydroxymethyl)-3-imino-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1⁷,¹¹.0¹,⁶]tetradecane-5,9,12,13,14-pentol
n-[1-(3,4-dihydroxyphenyl)-3-hydroxypropan-2-yl]-3,4-dihydroxybenzenecarboximidic acid
(1r,5r,6s,7r,9s,11r,12r,13s,14r)-14-(hydroxymethyl)-3-imino-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1⁷,¹¹.0¹,⁶]tetradecane-5,9,12,13,14-pentol
4-benzyl-3-hydroxy-4h-pyrazino[2,1-b]quinazoline-1,6-dione
C18H13N3O3 (319.09568680000007)
(1r,5r,6r,7r,9s,11s,13s,14s)-14-(hydroxymethyl)-3-imino-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1⁷,¹¹.0¹,⁶]tetradecane-5,9,12,13,14-pentol
(1r,5s,6r,7r,9s,11s,12r,13s,14s)-14-(hydroxymethyl)-3-imino-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1⁷,¹¹.0¹,⁶]tetradecane-5,9,12,13,14-pentol
methyl 2-(1,2-dimethoxy-2-oxoethyl)-1-methyl-4-oxoquinoline-3-carboxylate
(11s,12r)-11,12-dihydroxy-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4,6,8,15,17,19-octaen-14-one
C18H13N3O3 (319.09568680000007)
(4s)-4-benzyl-3-hydroxy-4h-pyrazino[2,1-b]quinazoline-1,6-dione
C18H13N3O3 (319.09568680000007)
methyl 4-methyl-6-(1,4,6-trihydroxy-3-oxoisoindol-5-yl)hex-4-enoate
methyl 2-[(1s)-1,2-dimethoxy-2-oxoethyl]-1-methyl-4-oxoquinoline-3-carboxylate
(1r,5r,6r,7r,9s,11s,13s,14r)-14-(hydroxymethyl)-3-imino-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1⁷,¹¹.0¹,⁶]tetradecane-5,9,12,13,14-pentol
(1r,5r,6s,7s,9s,11s,12s,13s,14s)-14-(hydroxymethyl)-3-imino-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1⁷,¹¹.0¹,⁶]tetradecane-5,9,12,13,14-pentol
n-[(2s)-1-(3,4-dihydroxyphenyl)-3-hydroxypropan-2-yl]-3,4-dihydroxybenzenecarboximidic acid
(1r,5r,6r,7r,9s,11s,12r,13s,14s)-14-(hydroxymethyl)-3-imino-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1⁷,¹¹.0¹,⁶]tetradecane-5,9,12,13,14-pentol
(1r,2r,3r,4s,5r,6r,7s,11r)-2,3,4,5-tetrahydroxy-4-(hydroxymethyl)-9-imino-12-oxa-8,10-diazatricyclo[5.3.2.0¹,⁶]dodecane-11-carboxylic acid
(11s,13s)-14-(hydroxymethyl)-3-imino-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1⁷,¹¹.0¹,⁶]tetradecane-5,9,12,13,14-pentol
(1r,5s,6r,7r,9s,11s,12s,13s,14s)-14-(hydroxymethyl)-3-imino-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1⁷,¹¹.0¹,⁶]tetradecane-5,9,12,13,14-pentol
10-hydroxy-10-[5-(hydroxymethyl)-1-methyl-2,4-dioxopyrrolidin-3-ylidene]deca-2,4,6,8-tetraenoic acid
(1r,5r,6r,7s,9r,11s,13s,14s)-14-(hydroxymethyl)-3-imino-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1⁷,¹¹.0¹,⁶]tetradecane-5,9,12,13,14-pentol
methyl 2-[(1r)-1,2-dimethoxy-2-oxoethyl]-1-methyl-4-oxoquinoline-3-carboxylate
11,12-dihydroxy-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4,6,8,15,17,19-octaen-14-one
C18H13N3O3 (319.09568680000007)